Dr Reddy's Laboratories Ltd
(STU:RDDA)
€
13.3
-0.2 (-1.48%)
Market Cap: 11.08 Bil
Enterprise Value: 10.96 Bil
PE Ratio: 23.15
PB Ratio: 3.28
GF Score: 90/100 Dr.Reddy's Laboratories Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021 / 04:00PM GMT
Release Date Price:
€11.7
(-0.85%)
Neha Manpuria
JPMorgan Chase & Co, Research Division - Analyst
Hello, and welcome to the JPMorgan Healthcare Conference. I am Neha Manpuria, the India Health Care Analyst at JPMorgan. It's my pleasure to introduce Mr. Erez Israeli, the CEO of Dr. Reddy's. We will be having a fireside chat in this session and try to address questions on growth strategies of Reddy's. Thank you so much for joining us for this session, sir. It is a pleasure to host you. If you don't mind me directly moving into Q&A, I can start.
Questions & Answers
Erez Israeli;s Laboratories Limited;CEO;Member of the Management Council
Dr. Reddy
'-&
Sure. Thank you for having me.
Neha Manpuria
JPMorgan Chase & Co, Research Division - Analyst
So the first question that I have is Dr. Reddy's today probably has a very well-balanced business with a growing emerging market presence, improving position in India post the Wockhardt acquisition and a strong U.S. pipeline. From here on,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot